Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XT-150 for Facet Joint Osteoarthritis Pain
NCT05196919Phase 2Completed
- Sponsor
- Xalud Therapeutics
- Start
- Feb 2022
- Primary completion
- Sep 2023
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 2 trial of XT-150 in facet joint osteoarthritis, sponsored by Xalud Therapeutics. Started Feb 2022; status: completed.
02
Drugs
XT-150
03
Conditions
facet joint osteoarthritis
Beyond the preview
Go deeper on NCT05196919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05196919.